Strategy+ is advising one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on the acquisition of Array BioPharma Inc. (NASDAQ: ARRY), a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. The definitive merger agreement was announced June 17, 2019. Pfizer has agreed to acquire Array for a total enterprise value of approximately $11.4 Billion in cash.
Note to Editors: This press release may contain forward-looking statements regarding Strategy+’s intentions and interests. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. The firm does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
